OUR FDA APPROVED INTERNAL TRIGGER POINT WAND
THE ONLY FDA APPROVED DEVICE FOR SELF-ADMINISTERING INTERNAL TRIGGER POINT RELEASE
Since we began the Wise-Anderson Protocol at Stanford University Medical Center in the department of Urology in the mid 1990’s, we recognized the need for a special device to do internal trigger point release self-treatment for those with pelvic floor dysfunction. In 2012, after a 4 year clinical trial with many patients, we received approval from the Food and Drug Administration based on evaluation of its safety and effectiveness.
Our Internal Trigger Point Wand (the Wand) is the first scientifically designed device for internal myofascial/trigger point release that has been in a clinical trial and whose results have been published by a peer-reviewed journal and presented in scientific meetings. In our study published in the Clinical Journal of Pain, after 6 months the median reduction in sensitivity/pain of trigger points of self-treatment reported by patients with pelvic pain reduced from 7.5 to 4 on a 1-10 scale. This is a remarkable result. In our experience, we have observed that there is usually a continual drop in trigger point sensitivity/pain beyond 6 months.
We presented the Wand at the International Continence Society in San Francisco in 2009 and at the American Physical Therapy Association Meetings in New Orleans in 2011 and the results of our Wand study were presented at the American Urological Association meetings in Washington in May, 2011. The abstract on our Internal Trigger Point Wand won an award at the American Urological Association meetings, was presented to the public in a press conference sponsored by the AUA, and was nominated for presentation in the AUA meetings in Tokyo.